% | $
Quotes you view appear here for quick access.

Anacor Pharmaceuticals, Inc. (ANAC) Message Board

  • c31973 c31973 Feb 19, 2013 7:33 PM Flag


    I believe investors are worried that Tavaborole is potentially (not for sure but possibly) inferior to Valeant’s Efinaconazole. If so, the revenue potential for Tavaborole is sharply diminished. The company only has 2-3 quarters of cash left. Thus, more dilutive share offerings are possibly coming.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Recent results, using an aged population in Mexico, showed results slightly below Valeant's Efinaconzole. Present testing, which results should be expected in March or early April, are using a more representative spread of the population and from a group more representative of the American-Euro population. Deustsche Bank wrote positive comments even with the original tests that said results from the newer test equal to the last tests would definitely qualify Tavaborole for movement into the marketplace.

      Sentiment: Strong Buy

108.485-6.445(-5.61%)3:32 PMEDT